Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flublok Quadrivalent vs IIV4 in Healthy Adults 18-49
NCT02290509Phase 3Completed
- Sponsor
- Protein Sciences
- Start
- Oct 2014
- Primary completion
- May 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of influenza vaccine, recombinant hemagglutinin in influenza (2 arms), sponsored by Protein Sciences. Primary endpoints: Seroconversion to Vaccine Antigens Following Vaccination at 28 days and Geometric Mean Titers of Antibodies to Vaccine Antigens at 28 days. Started Oct 2014; status: completed.
02
Drugs
influenza vaccine, recombinant hemagglutinin
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02290509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02290509.